Children with coronavirus disease 2019 (COVID19), an infection caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV2) are usually asymptomatic or only mildly symptomatic. The most common symptoms are coryzal in nature including fever and cough.1 Most children are clinically stable1 and require no medical intervention. However, despite their stable condition, stringent infection control measures are still required.
In this letter, we describe a child infected with SARSCoV2 who presented atypically with croup features. With the current COVID19 pandemic, infection control measures need to be appropriately heightened and early diagnostic sampling for SARSCoV2 should be carried out even in symptomatology that is atypical of COVID19.
A 21monthold boy was admitted with a 1day history of fever, noisy breathing, mild cough, and hoarseness. The cough was not barking and there were no drooling, gastrointestinal, or urinary symptoms. On examination, he was febrile at 40.2°C, respiratory rate was 3236/min and SpO2 was 94%97% in room air. He had hoarseness and exhibited inspiratory stridor during vigorous cry. Breath sounds were vesicular, air entry bilaterally equal and no other signs were present. The clinical features were compatible with mild croup.
In view of a history of close contact 5 days before admission with his maternal grandmother who was confirmed as SARSCoV2 positive 3 days ago he was tested for SARSCoV2. He tested positive for SARSCoV2 by nasopharyngeal swab (NPS) PCR on admission with a Ct value of 16.4. NPS was negative for other respiratory pathogens including adenovirus, human metapneumovirus, human enterovirus/rhinovirus, influenza A, influenza B, parainfluenza types 14, respiratory syncytial virus, Bordetella pertussis, Chlamydia pneumoniae, and Mycoplasma pneumoniae. The chest radiograph showed a positive steeple sign and no consolidation.
He was treated for croup with one dose of 0.6mg/kg oral dexamethasone on Day 1 of illness. The symptoms improved initially but deteriorated 12h after the first dexamethasone dose with worsening of tachypnoea and persistence of stridor with agitation. A second dose of 0.6mg/kg dexamethasone was given on Day 2 of illness. There was then gradual resolution of noisy breathing and tachypnoea. His cough and sputum sounds subsided on Day 9 but the hoarseness persisted till Day 15. NPS SARSCoV2 PCR Ct value rose to 31.78 by Day 9 and 35 by Day 18. Blood for SARSCoV2 antibody was positive by Day 19. The patient was asymptomatic by that time and was discharged.
Croup is a common viral infection in the pediatric population that is usually associated with parainfluenza, rhinovirus, and respiratory syncytial virus infections. Children with croup usually present with a characteristic barking cough, stridor, and respiratory distress. Compared with COVID19, for croup, the presentation and initial management strategies are distinctly different. Treatment including dexamethasone and nebulized adrenaline can be considered. Croup is usually diagnosed by clinical assessment. Healthcare workers deliberately avoid uncomfortable procedures such as bloodtaking and nasopharyngeal sampling in these children as agitating the child may worsen any airway obstruction. Croup symptoms usually last for 23 days and sometimes up to 1 week.
Our case was an uncommon manifestation of pediatric SARSCoV2 infection. Very few cases of SARSCoV2 infection presenting with features of croup have been reported in the literature. Pitstick et al.2 reported a SARSCoV2 positive case with fever, cough, and intermittent stridor, while Venn et al.3 reported three SARSCoV2 positive cases with the first case exhibiting fever, cough, and stridor; the second case cough and dyspnea without fever; and the third child fever, tachypnoea and inspiratory stridor at rest.
Our patient had persistent symptoms lasting 15 days which is much longer than the usual 23 days. Such prolonged symptomatology is unusual amongst pediatric COVID19 cases1 and also uncommon amongst children with croup. Apart from this, the presentation of croup caused by SARSCoV2 is similar to that of those caused by parainfluenza type 1. Patients described by Pitstick and Venn also had similar presentations as per usual parainfluenza croup, so whether SARSCoV2 can cause a longer duration of symptoms for croup remains to be seen.
Nasopharyngeal aspiration (NPA) is an aerosolgenerating procedure, that should be carried out in an airborne infection isolation room (AIIR) by staff protected with adequate personal protective equipment (PPE). In our practice, patients with croup usually are not tested for fear of the risk of airway obstruction when agitating the child. As symptoms of croup caused by parainfluenza virus and SARSCoV2 are similar, it would be difficult to differentiate the two by clinical assessment alone. However, the implications regarding aerosolgenerating procedures, isolation facilities, and treatment may be very different. Hence, under the current pandemic, we would recommend to proceed with early testing in children presenting with clinical features of croup so that appropriate treatment and infection control measures may be instituted. As there is a risk of worsening airway obstruction with sampling, expertise, and equipment needed for advanced airway support should be available while the patient is undergoing nasopharyngeal sampling. Instead of NPAs, alternative sampling such as throat swabs or NPSs for SARSCoV2 may be considered to minimize aerosol generation as much as possible.
Patients with croup are often treated with oral dexamethasone. For more serious cases, nebulized adrenaline may be considered. Should nebulized adrenaline be indicated, medical staff should wear full PPE and administer a nebulizer in AIIR. In case AIIR and adequate PPE are unavailable, there is limited evidence supporting the use of a metereddose inhaler for epinephrine delivery.4
Repeated doses of dexamethasone should be considered if appropriate. In case of deterioration, early intubation should be considered by medical personnel equipped with appropriate PPE and nebulized medication can be administered via a closed ventilatory circuit.
In conclusion, under the current COVID19 pandemic, even for children presenting atypically, for example, with croup, after careful consideration of patient’s clinical condition, availability of PPE and AIIR and choice of treatment, early testing for SARSCoV2 is still strongly recommended. Clinicians may consider waiting for approximately 2h for an initial dose of dexamethasone to take effect.5 Appropriate detection of children with SARSCoV2 infection is important to help prevent the spread of disease, and patients should also remain housed in an AIIR if possible.
CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.
AUTHOR CONTRIBUTIONS
Kathleen Tsoi: conceptualization (equal); writing original draft (equal); writing review and editing (equal). Kate C. Chan: conceptualization (equal); writing review and editing (equal). Geoffrey Mok: conceptualization (equal); supervision (equal). Albert M. Li: conceptualization (equal); supervision (equal); writing review and editing (equal). Hugh S. Lam: conceptualization (equal); supervision (equal); writing review and editing (equal).
KEYWORDS
COVID19, croup, viral infection, SARSCoV2